Skip to main content
Clinical Trials/NCT01284010
NCT01284010
Completed
Not Applicable

Genome-Wide Analysis of Genetic Alterations in Adult Acute Lymphoblastic Leukemia

Alliance for Clinical Trials in Oncology1 site in 1 country200 target enrollmentFebruary 2011
ConditionsLeukemia

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Leukemia
Sponsor
Alliance for Clinical Trials in Oncology
Enrollment
200
Locations
1
Primary Endpoint
disease free survival
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

RATIONALE: Studying samples of blood and bone marrow from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.

PURPOSE: This research study is studying biomarkers in blood and bone marrow samples from patients with acute lymphoblastic leukemia.

Detailed Description

OBJECTIVES: * To perform high-resolution, genome-wide profiling of DNA copy number alterations and loss-of-heterozygosity in samples from adult patients with acute lymphoblastic leukemia (ALL) obtained at diagnosis. * To perform candidate gene resequencing of diagnostic ALL samples. * To examine correlation of genetic alterations with outcome. * To examine the correlation between microarray multi-gene and multi-exon expression signatures with specific alterations and outcome. * To understand genetic events that contribute to the formation, development, and relapse of adult ALL by integrating the copy number and sequence alterations with the multi-gene signatures, and by comparing these data with data already generated in pediatric ALL. OUTLINE: Diagnostic, complete remission, and germ-line specimens are analyzed for DNA profiling and gene resequencing by the Affymetrix SNP6.0 microarray platform, PCR, and fluorescence in situ hybridization (FISH). Frequency of genetic alterations are performed by the Agilent 2100 Bioanalyzer. Results are then compared with the data already generated from pediatric patients.

Registry
clinicaltrials.gov
Start Date
February 2011
End Date
September 2014
Last Updated
6 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

disease free survival

Time Frame: Up to 7 Years

cumulative incidence of relapse

Time Frame: Up to 7 years

complete remission rate

Time Frame: Up to 7 Years

overall survival

Time Frame: Up to 7 years

event-free survival

Time Frame: Up to 7 years

Study Sites (1)

Loading locations...

Similar Trials